Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common

Malaria Journal

Review

Lucio Luzzatto¹  Gao Qi²  Nicholas J White³  Li Guo Qiao⁴ 

[1] Istituto Toscano Tumori, Florence, Italy;Jiangsu Institute of Parasitic Diseases, Wuxi, China;Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;Research Centre for Qinghao, Guangzhou University of Chinese Medicine, Guangzhou, China;

关键词: Malaria;    Falciparum Malaria;    G6PD Deficiency;    Primaquine;    G6PD Activity;   

DOI  :  10.1186/1475-2875-11-418

 received in 2012-10-14, accepted in 2012-11-28,  发布年份 2012

来源: Springer

【 摘 要 】

In areas of low malaria transmission, it is currently recommended that a single dose of primaquine (0.75 mg base/kg; 45 mg adult dose) be added to artemisinin combination treatment (ACT) in acute falciparum malaria to block malaria transmission. Review of studies of transmission-blocking activity based on the infectivity of patients or volunteers to anopheline mosquitoes, and of haemolytic toxicity in glucose 6-dehydrogenase (G6PD) deficient subjects, suggests that a lower primaquine dose (0.25 mg base/kg) would be safer and equally effective. This lower dose could be deployed together with ACTs without G6PD testing wherever use of a specific gametocytocide is indicated.

【 授权许可】

CC BY   
© White et al.; licensee BioMed Central Ltd. 2012